Key facts
- Biographica’s last known valuation is $33.8M (Jan 2026).
- It has raised $11.6M; the latest was Seed Round ($9.4M) in Jan 2026.
- Notable investors include Entrepreneurs First, StartLife, Ventures Together, Faber Ventures, Chalfen Ventures — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Biographica
- ·The full record, as it builds
Funding rounds
No funding rounds for Biographica are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Biographica
Developer of a genomics platform designed to accelerate the growth of productive, sustainable, nutritious, and climate-resilient food sources. The company's platform uses proprietary molecular data and a multi-modal graph-centric approach to identify and prioritize high-value targets for crop gene editing, enabling ag-biotech companies to rapidly identify novel genetic targets for enhanced crop traits, improving productivity and sustainability.
- Sector
- Materials and Resources
- HQ
- London, United Kingdom
- Founded
- 2022
- Employees
- 8
- Website
- graphica.bio/
- Ownership
- Privately Held (backing)
Biographica doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Biographica shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Biographica in its N-PORT filings yet. We sweep new filings monthly.